
---
title: '奥赛康：子公司药品获得药品注册批准'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=4075'
author: 证券时报网
comments: false
date: Thu, 21 Oct 2021 16:45:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=4075'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="http://info.stcn.com/dc/stock/?stockcode=SZ002755" style="color: #2f67d1;text-decoration: none;" code="002755" target="_blank">奥赛康</a>(002755)10月21日晚间公告，子公司江苏<a class="trsHotWords" href="http://info.stcn.com/dc/stock/?stockcode=SZ002755" style="color: #2f67d1;text-decoration: none;" code="002755" target="_blank">奥赛康</a>药业有限公司的注射用多黏菌素E甲磺酸钠于近日获得药监局的药品注册批准；注射用唑来膦酸浓溶液获得药品注册上市申请受理通知书。</p>

                  
</div>
            